SG11202113221RA - Anti-cd137l antibodies and methods of using same - Google Patents
Anti-cd137l antibodies and methods of using sameInfo
- Publication number
- SG11202113221RA SG11202113221RA SG11202113221RA SG11202113221RA SG11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA SG 11202113221R A SG11202113221R A SG 11202113221RA
- Authority
- SG
- Singapore
- Prior art keywords
- cd137l
- antibodies
- methods
- same
- cd137l antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019090091 | 2019-06-05 | ||
| PCT/CN2020/094371 WO2020244574A1 (en) | 2019-06-05 | 2020-06-04 | Anti-cd137l antibodies and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113221RA true SG11202113221RA (en) | 2021-12-30 |
Family
ID=73652442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113221RA SG11202113221RA (en) | 2019-06-05 | 2020-06-04 | Anti-cd137l antibodies and methods of using same |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220089757A1 (en) |
| EP (1) | EP3980461A1 (en) |
| JP (1) | JP2022535538A (en) |
| CN (1) | CN114450305A (en) |
| AU (1) | AU2020287181A1 (en) |
| CA (1) | CA3139968A1 (en) |
| SG (1) | SG11202113221RA (en) |
| WO (1) | WO2020244574A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2015094123A1 (en) * | 2013-12-20 | 2015-06-25 | National University Of Singapore | Differentiation therapy with cd137 ligand agonists |
| EP3394107A1 (en) * | 2015-12-22 | 2018-10-31 | AbbVie Stemcentrx LLC | Novel anti-tnfsf9 antibodies and methods of use |
| EP3423078A4 (en) * | 2016-03-03 | 2019-11-06 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
| CA3059366A1 (en) * | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| KR20180119135A (en) * | 2017-04-24 | 2018-11-01 | 주식회사 제넥신 | 4-1bbl variant and fused protein comprising same |
| WO2019036855A1 (en) * | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
-
2020
- 2020-06-04 CN CN202080050302.3A patent/CN114450305A/en active Pending
- 2020-06-04 CA CA3139968A patent/CA3139968A1/en active Pending
- 2020-06-04 AU AU2020287181A patent/AU2020287181A1/en not_active Abandoned
- 2020-06-04 EP EP20817646.1A patent/EP3980461A1/en not_active Withdrawn
- 2020-06-04 US US17/612,878 patent/US20220089757A1/en not_active Abandoned
- 2020-06-04 WO PCT/CN2020/094371 patent/WO2020244574A1/en not_active Ceased
- 2020-06-04 SG SG11202113221RA patent/SG11202113221RA/en unknown
- 2020-06-04 JP JP2021571753A patent/JP2022535538A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139968A1 (en) | 2020-12-10 |
| CN114450305A (en) | 2022-05-06 |
| JP2022535538A (en) | 2022-08-09 |
| AU2020287181A1 (en) | 2022-01-20 |
| WO2020244574A1 (en) | 2020-12-10 |
| EP3980461A1 (en) | 2022-04-13 |
| US20220089757A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| EP4031177A4 (en) | Anti-tnfr2 antibodies and methods of use | |
| IL280225A (en) | Novel cd47 antibodies and methods of using same | |
| SG11202108403UA (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| IL287282A (en) | Anti-mertk antibodies and their methods of use | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL288886A (en) | Antibodies and methods of use | |
| SG11202113221RA (en) | Anti-cd137l antibodies and methods of using same | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| ZA202201160B (en) | Anti-grp78 antibodies and method of use thereof | |
| HK40105211A (en) | Anti-ly6g6d antibodies and methods of use | |
| HK40082835A (en) | Anti-ly6g6d antibodies and methods of use | |
| HK40081755A (en) | Anti-ror-2 antibodies and methods of use | |
| HK40066875A (en) | Antibodies and methods of use | |
| HK40070022A (en) | Anti-mertk antibodies and their methods of use |